Vicore Pharma Holding AB (publ) - Asset Resilience Ratio
Vicore Pharma Holding AB (publ) (VICO) has an Asset Resilience Ratio of 48.38% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check VICO capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2018–2025)
This chart shows how Vicore Pharma Holding AB (publ)'s Asset Resilience Ratio has changed over time. See VICO net asset quality index to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Vicore Pharma Holding AB (publ)'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Vicore Pharma Holding AB (publ) (VICO) market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr0.00 | 0% |
| Short-term Investments | Skr590.06 Million | 48.38% |
| Total Liquid Assets | Skr590.06 Million | 48.38% |
Asset Resilience Insights
- Very High Liquidity: Vicore Pharma Holding AB (publ) maintains exceptional liquid asset reserves at 48.38% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Vicore Pharma Holding AB (publ) Industry Peers by Asset Resilience Ratio
Compare Vicore Pharma Holding AB (publ)'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC |
Biotechnology | -55.36% |
|
Krystal Biotech Inc
NASDAQ:KRYS |
Biotechnology | 23.06% |
|
Verona Pharma PLC ADR
NASDAQ:VRNA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
BB Biotech AG
SW:BION |
Biotechnology | 0.05% |
Annual Asset Resilience Ratio for Vicore Pharma Holding AB (publ) (2018–2025)
The table below shows the annual Asset Resilience Ratio data for Vicore Pharma Holding AB (publ).
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 48.38% | Skr590.06 Million ≈ $63.50 Million |
Skr1.22 Billion ≈ $131.25 Million |
-- |
| 2024-12-31 | 0.00% | Skr0.00 ≈ $0.00 |
Skr1.20 Billion ≈ $129.47 Million |
-- |
| 2023-12-31 | 29.94% | Skr149.04 Million ≈ $16.04 Million |
Skr497.84 Million ≈ $53.58 Million |
+28.48pp |
| 2022-12-31 | 1.46% | Skr4.94 Million ≈ $531.62K |
Skr338.01 Million ≈ $36.37 Million |
-15.61pp |
| 2021-12-31 | 17.07% | Skr77.00 Million ≈ $8.29 Million |
Skr451.17 Million ≈ $48.55 Million |
-0.15pp |
| 2020-12-31 | 17.22% | Skr70.00 Million ≈ $7.53 Million |
Skr406.51 Million ≈ $43.75 Million |
-5.35pp |
| 2019-12-31 | 22.57% | Skr77.00 Million ≈ $8.29 Million |
Skr341.11 Million ≈ $36.71 Million |
+22.57pp |
| 2018-12-31 | 0.01% | Skr21.00K ≈ $2.26K |
Skr301.60 Million ≈ $32.46 Million |
-- |
About Vicore Pharma Holding AB (publ)
Vicore Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases in Sweden. The company develops Buloxibutid (C21), an orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) that is in Phase II clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF), as well as in Phase I clinical trial f… Read more